Abstract: Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2X7 protein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2X7 in cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2X7 in cells are described.

Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.

Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor as at proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.

Abstract: A computer implemented method of mapping of multiple regional center point trajectory movements of cavity walls is provided in which images are acquired and a region-of-interest is identified in each of the images. The region-of-interest is divided into a plurality of distinct regions and a regional center point for each of the regions is located in the images. For each regional center point, a center point trajectory is determined based on variances in position of the center points from each other in the images. The center point trajectory of each regional center point is decomposed into radial and circumferential components so as to isolate radial component of the center point trajectory for each regional center point in each of the images and radial motion versus time curves are displayed for each regional center point based on the determined radial component for each regional center point in each of the images.

Abstract: Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.

Abstract: The present disclosure relates to amyloid beta (A?) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block A? channel activity and/or reduce A?-induced toxicity in a cell. Compositions comprised of compounds having histidine coordinating capacity are used in methods to prevent, reduce, or eliminate damage caused by A? ion channels.

Abstract: Embodiments relate to systems and methods for a cranial implant assembly adapted for insertion during a craniectomy procedure. In aspects, the inventive cranial implant assembly can contain a peripheral attachment member for attachment to the edge of a skull opening, as well as an articulated spanning member that over-arches and holds a cover in place over the opening. The articulated spanning member contains a central implant fastened or connected to a swollen dura in the skull opening. As swelling of the dura subsides, tension is exerted on guidewires in both the spanning member and cover to draw those constructs into a rigid state. The tips of the spanning member can gradually approach the peripheral attachment member, and register into place using a locking mechanism, such as a pair of opposing magnets. As a result, only one surgical operation or procedure Is required to both perform a craniectomy and implant a supporting assembly for eventual skull regeneration.

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.

Abstract: Embodiments relate to systems and methods for magnetized stent having growth-promoting properties. A stent assembly comprising a tubular elongated body having a magnetized region and a tissue nidus area is inserted beneath the orifice of a vascular aneurysm. The magnetic region can serve to attract and position both residual red blood cells and magnetically nano-ireated growth-promoting cells to the orifice area of the aneurysm. The outer circumference of the tubular elongated body can act as a floor or scaffold for regenerated smooth vascular muscle cells. In embodiments, the tissue nidus area can be provided on the exterior stent, while the magnetized region is provided on the interior stent, of a stent-in-stent structure. In embodiments, the exterior stent is made of biodegradable material which gradually dissolves or dissipates in situ.

Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.

Abstract: A method is provided for separating diagnostic content of x-ray images from non-diagnostic content in order to achieve an optimum image reproduction and windowing. In particular, a method is provided for displaying a plurality of radiological density images in a single viewing window by overlaying gray scale images of each radiological density image in a single display window.

Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.

Abstract: The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.

Abstract: The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.

Abstract: Methods, kits, primers and oligonucleotide probes for conveniently and rapidly detecting and identifying four or more human adenovirus (HAdV) serotypes in a sample are provided. Following a nucleic acid amplification reaction with specific primers, serotype specific oligonucleotide probes are used not only to detect HAdV present in a sample but also to discriminate between the HAdV serotypes present in the sample, and in particular to discriminate between the clinically relevant serotypes HAdV-3, HAdV-4, HAdV-7, HAdV-14, and HAdV-21 and/or HAdV-I, HAdV-2, HAdV-5, and HAdV-6. The combination of these primers and oligonucleotide probes permit the rapid and convenient serotyping of HAdV.

Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.

Abstract: The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (c?Stx1) and anti-Shiga Toxin 2 (c?Stx2) antibodies.

Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.

Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG anti-body. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.